Aureka, an AI-driven drug discovery startup, has raised a $100 million Series B round to advance its biological foundation model, AuraIDE, and challenge AlphaFold's dominance in the AI for Science (AI4S) space.
TL;DR
- Aureka raises $100M Series B to advance its AuraIDE model and compete with AlphaFold in AI4S.
- The funding will support R&D, model development, and industry collaboration in AI-driven drug discovery.
- Aureka's open-sourcing of OpenDDE demonstrates its commitment to the global biological foundation model competition.
What happened
Aureka, founded in 2023 by serial entrepreneur and former Harvard Medical School postdoc ZHAO Wei'an, has closed a $100 million Series B funding round. The round was led by Granite Asia, with participation from industrial investors, HLC Fund, and existing shareholders including Qiming Venture Partners, Matrix Partners China, and New Alliance Capital. This follows a $35 million Series A+ round just three months prior.
The funding will be used to accelerate the development of Aureka's biological foundation model, AuraIDE, and its high-throughput digital biology platform. The company aims to challenge the current market leader, AlphaFold, in the AI for Science (AI4S) space, particularly in drug discovery and development.
Why it matters
Aureka's approach focuses on using AI to raise the upper limit of intelligence through scientific discovery, rather than just cutting costs and improving efficiency. This aligns with the growing recognition of the Scaling Law demonstrated by biological foundation models, which shows that stronger model capabilities lead to better performance in structural prediction accuracy and the differentiation of generated candidate molecules.
The funding will enable Aureka to invest in kilocalorie-scale computing power and further develop its AuraIDE model, which could lead to breakthroughs in drug discovery and development. The company's open-sourcing of OpenDDE, a biological structure modeling capability, demonstrates its commitment to entering the global competition arena of biological foundation models.
Key facts
- Aureka raises $100 million Series B round, led by Granite Asia, with participation from industrial investors and existing shareholders.
- The company has already generated tens of millions of dollars in revenue from its AI-driven drug discovery platform.
- Aureka's AuraIDE model and high-throughput digital biology platform form a closed loop connecting AI design and wet experimental verification.
- The company open-sourced OpenDDE, a biological structure modeling capability, in July 2026.
- Aureka aims to challenge AlphaFold's dominance in the AI4S space, particularly in drug discovery and development.
- The funding will support R&D, model development, and industry collaboration in AI-driven drug discovery.
Context
The AI for Science (AI4S) space is gaining traction as capital pours into the sector in 2026. The breakthroughs in AI capabilities, particularly in biological foundation models, have made AI4S a high-quality application scenario that can be implemented. This has led to a renewed interest in the track, with investment institutions seeing the opportunity to form a commercial closed loop and achieve capital exit in the AI pharmaceutical sector.
Aureka's approach of using AI to raise the upper limit of intelligence through scientific discovery is gaining recognition. The company's open-sourcing of OpenDDE demonstrates its commitment to entering the global competition arena of biological foundation models, which could lead to breakthroughs in drug discovery and development.
